Puma Biotechnology Inc Quick Ratio (PBYI) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Puma Biotechnology Inc   (NASDAQ: PBYI)

Puma Biotechnology Inc 's Quick Ratio

PBYI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Puma Biotechnology Inc 's Cash & cash equivalent grew by 41.97 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Puma Biotechnology Inc 's Quick Ratio to 2.89, Quick Ratio remained below Puma Biotechnology Inc average.

Within Major Pharmaceutical Preparations industry 238 other companies have achieved higher Quick Ratio than Puma Biotechnology Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1137, from total ranking in the first quarter 2026 at 1160.

Explain Quick Ratio?
How much Cash & cash equivalents PBYI´s has?
What are PBYI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PBYI Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -37.01 % -31.07 % -15.46 % -25.06 % -24.16 %
Y / Y Cash & cash equivalent Change 50.13 % 8.99 % -3.4 % -2.42 % -0.83 %
Quick Ratio MRQ 2.89 1.7 1.2 1.14 1.21
PBYI's Total Ranking # 1137 # 1160 # 1091 # 1436 # 1306
Seq. Current Liabilities Change -16.59 % -26.48 % -1.78 % 4.59 % -8.73 %
Seq. Cash & cash equivalent Change 41.97 % 4.12 % 3.33 % -1.7 % 3.07 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 239
Healthcare Sector # 410
Overall Market # 1137


Quick Ratio Statistics
High Average Low
92.86 4.39 0.12
(Dec 31 2011)   (Sep 30 2011)




Financial Statements
Puma Biotechnology Inc 's Current Liabilities $ 50 Millions Visit PBYI's Balance sheet
Puma Biotechnology Inc 's Cash & cash equivalent $ 144 Millions Visit PBYI's Balance sheet
Source of PBYI's Sales Visit PBYI's Sales by Geography


Cumulative Puma Biotechnology Inc 's Quick Ratio

PBYI's Quick Ratio for the trailling 12 Months

PBYI Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -26.52 % -23.81 % -19.38 % -15.83 % 1.61 %
Y / Y Cash & cash equivalent TTM Growth 13.12 % 0.46 % -5.12 % 6.52 % 10.76 %
Quick Ratio TTM 1.6 1.29 1.16 1.12 1.04
Total Ranking TTM # 3993 # 2730 # 1481 # 2046 # 3007
Seq. Current Liabilities TTM Growth -9.67 % -8.17 % -4.31 % -7.43 % -6.34 %
Seq. Cash & cash equivalent TTM Growth 12.36 % 2.2 % -0.89 % -0.6 % -0.21 %

Quick ratio ranking by company, industry and sector >> Back to PBYI Financial Strength Comparisons >> Go to Compare PBYI Quick Ratio to its Competitors

On the trailing twelve months basis PBYI Cash & cash equivalent soared by 50.13 % in Q2 2026 year on year, while Current Liabilities faded to $50 millions, this led to increase in in Puma Biotechnology Inc 's Quick Ratio to 1.6, above PBYI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 437 other companies have achieved higher Quick Ratio than Puma Biotechnology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2730 to 3993.

Explain Quick Ratio?
How much Cash & cash equivalents PBYI´s has?
What are PBYI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 438
Healthcare Sector # 900
Within the Market # 3993


trailing twelve months Quick Ratio Statistics
High Average Low
4.2 1.58 0.52
(Sep 30 2013)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Rocket Pharmaceuticals Inc   7.79 $ 342.940  Millions$ 44.031  Millions
Milestone Pharmaceuticals Inc   7.73 $ 171.481  Millions$ 22.184  Millions
Nuvation Bio Inc   7.62 $ 660.956  Millions$ 86.755  Millions
Ibio inc   7.50 $ 88.049  Millions$ 11.745  Millions
Promis Neurosciences inc   7.41 $ 53.463  Millions$ 7.218  Millions
Lakewood-Amedex Biotherapeutics Inc.  7.29 $ 4.585  Millions$ 0.629  Millions
Aspire Biopharma Holdings Inc   7.22 $ 12.167  Millions$ 1.686  Millions
Cartesian Therapeutics Inc   7.18 $ 147.606  Millions$ 20.550  Millions
Kiora Pharmaceuticals Inc   7.10 $ 16.839  Millions$ 2.370  Millions
Arvinas Inc   6.88 $ 567.900  Millions$ 82.500  Millions
Summit Therapeutics Inc   6.67 $ 690.749  Millions$ 103.566  Millions
Alumis inc   6.59 $ 502.300  Millions$ 76.233  Millions
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions
Aquestive Therapeutics Inc   5.98 $ 98.490  Millions$ 16.478  Millions
Xencor Inc  5.94 $ 486.350  Millions$ 81.865  Millions
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions
Emmis Acquisition Corp   5.72 $ 0.708  Millions$ 0.124  Millions
Arcturus Therapeutics Holdings Inc   5.71 $ 191.483  Millions$ 33.536  Millions
Hoth Therapeutics Inc   5.70 $ 7.892  Millions$ 1.384  Millions
Silence Therapeutics Plc  5.67 $ 72.100  Millions$ 12.714  Millions
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions

Date modified: 2026-09-26T07:02:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.